Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Kenoki Ohuchida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4792-1168; OpenAlex author ID A5061289037. Sources: OpenAlex.

Their work

Papers
76 (first author 39, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2011: 5 papers · 2012: 5 papers · 2013: 8 papers · 2014: 4 papers · 2015: 4 papers · 2016: 6 papers · 2017: 8 papers · 2018: 3 papers · 2019: 5 papers · 2020: 5 papers · 2021: 6 papers · 2022: 2 papers · 2023: 3 papers · 2024: 8 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 76

  1. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  2. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.surg.2026.110423↗
  3. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. First author DOI 10.1007/s00432-025-06095-z↗
  4. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-025-29823-4↗
  5. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  6. Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer. Co-author DOI 10.1111/cas.16060↗
  7. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  8. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1004↗
  9. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Co-author DOI 10.1186/s13046-024-03060-5↗
  10. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  11. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-024-03192-8↗
  12. [Microbiome in the Therapy for the Pancreatic Cancer]. Co-author PMID 39009514↗
  13. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. First author DOI 10.1007/s00432-022-04554-5↗
  14. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). Co-author DOI 10.1007/s00464-023-10438-7↗
  15. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Co-author DOI 10.1111/cas.15901↗
  16. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. First author DOI 10.1186/s13046-022-02301-9↗
  17. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. First author DOI 10.3390/cancers14163994↗
  18. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
  19. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. First author DOI 10.1016/j.canlet.2021.04.013↗
  20. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Co-author DOI 10.1016/j.cell.2021.07.020↗
  21. PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer. Co-author DOI 10.1016/j.jare.2021.02.002↗
  22. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Co-author DOI 10.1016/j.pan.2021.04.002↗
  23. Efficient pre-treatment for pancreatic cancer using chloroquine-loaded nanoparticles targeting pancreatic stellate cells. Co-author DOI 10.3892/ol.2021.12894↗
  24. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neo… Co-author DOI 10.1007/s00595-019-01852-3↗
  25. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. Co-author DOI 10.1097/cji.0000000000000305↗
  26. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. First author DOI 10.1371/journal.pone.0228015↗
  27. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. First author DOI 10.3892/ijo.2019.4951↗
  28. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Co-author DOI 10.7150/thno.47001↗
  29. An In Vitro Three-Dimensional Organotypic Model to Analyze Peripancreatic Fat Invasion in Pancreatic Cancer: A Culture System Based on Collagen Gel Embedding. First author DOI 10.1007/978-1-4939-8879-2_11↗
  30. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. First author DOI 10.1007/s00432-019-02860-z↗
  31. Robust 3D image reconstruction of pancreatic cancer tumors from histopathological images with different stains and its quantitative performance evaluation. Co-author DOI 10.1007/s11548-019-02019-8↗
  32. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. First author DOI 10.1016/j.canlet.2018.12.005↗
  33. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. First author DOI 10.3892/ijo.2019.4812↗
  34. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. First author DOI 10.1016/j.canlet.2017.10.010↗
  35. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2018.03.031↗
  36. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6761-6↗
  37. Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence. First author DOI 10.1007/s00268-017-4068-6↗
  38. Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2017.08.009↗
  39. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. First author DOI 10.1016/j.surg.2016.10.035↗
  40. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
  41. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
  42. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancr… First author DOI 10.18632/oncotarget.15430↗
  43. Cancer-associated peritoneal mesothelial cells lead the formation of pancreatic cancer peritoneal dissemination. First author DOI 10.3892/ijo.2016.3829↗
  44. Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients. First author DOI 10.3892/ol.2017.6549↗
  45. CD146 attenuation in cancer-associated fibroblasts promotes pancreatic cancer progression. First author DOI 10.1002/mc.22409↗
  46. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sid… First author DOI 10.1007/s00268-016-3526-x↗
  47. Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. First author DOI 10.1016/j.canlet.2016.01.016↗
  48. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. Co-author DOI 10.1111/cas.13024↗
  49. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. First author DOI 10.3892/ijo.2016.3374↗
  50. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Co-author DOI 10.3892/ijo.2016.3389↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 37 shared papers, 2011–2026 · strength 4.43
  2. Masafumi Nakamura · 37 shared papers, 2012–2024 · strength 3.96
  3. Yoshinao Oda · 34 shared papers, 2011–2026 · strength 3.41
  4. Naoki Ikenaga · 28 shared papers, 2011–2026 · strength 3.38
  5. Takao Ohtsuka · 45 shared papers, 2011–2026 · strength 2.85
  6. Chika Iwamoto · 21 shared papers, 2017–2025 · strength 2.63
  7. Toshiya Abe · 23 shared papers, 2016–2026 · strength 2.59
  8. Noboru Ideno · 12 shared papers, 2013–2026 · strength 1.80
  9. Koji Shindo · 19 shared papers, 2012–2024 · strength 1.65
  10. Yoshihiro Miyasaka · 22 shared papers, 2015–2021 · strength 1.49
  11. Tomohiko Shinkawa · 8 shared papers, 2020–2025 · strength 1.30
  12. Chikanori Tsutsumi · 6 shared papers, 2024–2025 · strength 1.13
  13. Takashi Okumura · 15 shared papers, 2016–2021 · strength 1.08
  14. Kazuhiro Koikawa · 13 shared papers, 2017–2024 · strength 1.05
  15. Koki Oyama · 6 shared papers, 2023–2025 · strength 1.03
  16. Masao Tanaka · 27 shared papers, 2011–2017 · strength 0.98
  17. Masataka Hayashi · 5 shared papers, 2023–2024 · strength 0.87
  18. Shin Kibe · 10 shared papers, 2017–2023 · strength 0.84
  19. Makoto Hashizume · 14 shared papers, 2011–2020 · strength 0.78
  20. Yusuke Mizuuchi · 8 shared papers, 2015–2025 · strength 0.77
  21. Pingshan Zhong · 5 shared papers, 2021–2024 · strength 0.75
  22. Akiko Sagara · 7 shared papers, 2017–2024 · strength 0.74
  23. Masafumi Nakamura · 9 shared papers, 2016–2024 · strength 0.74
  24. Sho Endo · 11 shared papers, 2017–2021 · strength 0.72
  25. Hideya Onishi · 4 shared papers, 2020–2026 · strength 0.71

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.